Dosage conversions as a potential cause of adverse drug events

American Journal of Health-System Pharmacy

Volumn 60, Issue 2, 2003, Pages 189-191

  Huckleberry, Yvonne ^a   Thomas, Michael C ^b   Erstad, Brian L ^c  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b MUNSON MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ESMOLOL; LABETALOL; METOPROLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CLINICAL PRACTICE; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; FOOD DRUG INTERACTION; HUMAN; HYPERTENSION; MALE; MEDICAL LITERATURE; PHARMACIST; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0037439562     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.2.189     Document Type: Article

References (16)

1. Bates DW, Cullen DJ, Laird N et al. Incidence of adverse drug events and potential adverse drug events. JAMA. 1995; 274:29-34.
2. Lopressor package insert. East Hanover, NJ: Novartis; 1999 Apr.
3. McEvoy GK, ed. AHFS drug information 2002. Bethesda, MD: American Society of Health-System Pharmacists; 2002.
4. Cada DJ, ed. Drug facts and comparisons. St. Louis, MO: Wolters Kluwer; 2002.
5. Micromedex Healthcare Series [CD-ROM]. Greenwood Village, CO: Micromedex; expires 2002 Mar.
6. Donnelly AJ, Cunningham FE, Baughman VL. Anesthesiology and critical care drug handbook. 4th ed. Cleveland, OH: Lexi-Comp; 2001.
7. 1-receptor antagonist metoprolol. Acta Pharmacol Toxicol. 1975; 36(suppl 5):31-44.
8. 1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm. 1974; 2:347-64.
9. Lennard MS, Silas JH, Freestone S et al. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol. 1982; 14:301-3.
10. Richard J, Cardot JM, Godbillon J. Inter- and intra-subject variability of metoprolol kinetics after intravenous administration. Eur J Drug Metab Pharmacokinet. 1994; 19:157-62.
11. Sannerstedt R, Wasir H. Acute haemodynamic effects of metoprolol in hypertensive patients. Br J Clin Pharmacol. 1977; 4:23-6.
12. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 2nd ed. Beckenham, United Kingdom: Lea & Febiger; 1989.
13. Rudy AC, Brater CD. Pharmacokinetics. In: Chernow B, ed. The pharmacologic approach to the critically ill patient. 3rd ed. Baltimore: Williams & Wilkins; 1994: 3-17.
14. McKindley DS, Hanes S, Boucher BA. Hepatic drug metabolism in critical illness. Pharmacotherapy. 1998; 18:759-78.
15. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157: 2413-46.
16. Erstad BL, Barletta JF. Treatment of hypertension in the perioperative patient. Ann Pharmacother. 2000; 34:66-79.